AHA, Others Comment to DEA on Controlled Substances Quotas

The AHA and six other organizations comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.  Although the organizations support DEA’s efforts to combat diversion, there is concern that the proposed rule is focused on diversion to the exclusion of another critical factor – drug shortages. 

Key Resources

Related Resources

Letter/Comment
Groups Voice Support for Drug Shortages Bill; FDA Reports on Root Causes
Public
The AHA, American Society of Anesthesiologists, American
AHA Center for Health Innovation Market Scan
Civica Rx Delivers First Generic Drug
In what is being hailed as a model for provider-led innovation, Civica Rx, the startup formed last year by a group of health systems to combat rising drug…
Letter/Comment
AHA Comments on DEA’s Proposed Aggregate Production Quotas for Controlled Substances, Schedule I and II
Public
The AHA appreciates the opportunity to comment on the Drug Enforcement Administration’s proposed notice on aggregate production quotas for schedule I and II…
Letter/Comment
AHA’s Feedback on the Public Meeting, “Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
Public
AHA provides feedback on the Food and Drug Administration’s request for comments on the public meeting, “Identifying the Root Causes of Drug Shortages and…
Letter/Comment
AHA Comments on HHS' Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Public
AHA comments on the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Letter/Comment
Group letter re: DEA’s proposed rule on controlled substances quotas
The undersigned groups thank the Drug Enforcement Administration (DEA) for the opportunity to comment on its proposed rule regarding controlled sub